<DOC>
	<DOCNO>NCT02420821</DOCNO>
	<brief_summary>This multi-center , randomize , open-label study evaluate efficacy safety atezolizumab ( MPDL3280A ) plus bevacizumab versus sunitinib participant inoperable , locally advanced , metastatic renal cell carcinoma ( RCC ) receive prior systemic active experimental therapy , either adjuvant metastatic setting .</brief_summary>
	<brief_title>A Study Atezolizumab Combination With Bevacizumab Versus Sunitinib Participants With Untreated Advanced Renal Cell Carcinoma IMmotion151</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Definitive diagnosis unresectable locally advanced metastatic RCC clearcell histology and/or component sarcomatoid carcinoma , prior treatment metastatic setting Evaluable Memorial Sloan Kettering Cancer Center risk score Measurable disease , define RECIST v1.1 Karnofsky performance status great equal 70 % Adequate hematologic endorgan function prior randomization DiseaseSpecific Exclusions : Radiotherapy RCC within 14 day prior treatment Active central nervous system disease Uncontrolled pleural effusion , pericardial effusion , ascites Uncontrolled hypercalcemia Any malignancy within 5 year except lowrisk prostate cancer negligible risk metastasis death General Medical Exclusions : Life expectancy le 12 week Participation another experimental drug study within 4 week prior treatment Pregnant lactating woman Known hypersensitivity component atezolizumab study medication History autoimmune disease except control , treat hypothyroidism type I diabetes mellitus History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis Positive human immunodeficiency virus test Active chronic hepatitis B C Severe infection within 4 week prior treatment Exposure oral IV antibiotic within 2 week prior treatment Live attenuate vaccine within 4 week prior treatment , 28 day prior randomization , treatment , within 5 month follow last dose atezolizumab Significant cardiovascular disease Prior allogeneic stem cell solid organ transplantation Exclusion Criteria Related Medications : Prior treatment cluster differentiation 137 agonist , anticytotoxic Tlymphocyte associate protein4 , antiprogrammed death ( PD ) 1 , antiPDL1 therapeutic antibody pathwaytargeting agent Treatment immunostimulatory agent nonmalignant condition within 6 week immunosuppressive agent within 2 week prior treatment Bevacizumab SunitinibSpecific Exclusions : History hypertensive crisis hypertensive encephalopathy Baseline electrocardiogram show correct QT interval great 460 millisecond</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>